title: Treatment of recurrent metastatic colon cancer in the age of modern adjuvant therapy.
abstract: The treatment of patients with metastatic colon cancer has evolved tremendously over the past 10 years, with improved overall survival (OS) rates as a result of the advent of several important agents. Following the results of important adjuvant trials, the incorporation of oxaliplatin into the adjuvant setting has significantly increased the disease-free survival and OS rates in patients who undergo curative resection. However, still a significant number of patients will present with recurrent disease after being treated with oxaliplatin-containing chemotherapy regimens. Herein, we present approaches to the chemotherapeutic management of such patients with a review of the literature.
authors.affiliation: Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD 20892, USA.
authors.forename: Carla
authors.initials: C
authors.lastname: Kurkjian
authors.forename: Anthony J
authors.initials: AJ
authors.lastname: Murgo
authors.forename: Shivaani
authors.initials: S
authors.lastname: Kummar
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage*; D003110:Colonic Neoplasms / Q000401:mortality / Q000473:pathology* / Q000628:therapy*; D003131:Combined Modality Therapy; D004359:Drug Therapy, Combination; D006801:Humans; D009364:Neoplasm Recurrence, Local / Q000401:mortality* / Q000473:pathology / Q000628:therapy*; D015996:Survival Rate
chemical_list: D000970:Antineoplastic Agents